The state of New Jersey currently has 425 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including New Brunswick, Hackensack, Newark and Morristown.
sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)
NCT05332002
Recruiting
The primary objective is to determine the clinical efficacy of treatment regimen in terms of objective response rate (ORR). The secondary objectives is to determine the clinical efficacy of the study treatment in terms of progression free survival (PFS) and overall survival (OS). Additionally, to characterize the safety and toxicity profile of the study treatment as measured by the adverse event rates.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2023
Locations: RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton, New Jersey +5 locations
Conditions: Gastro-Intestinal Cancer
Register for Updates
Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy
NCT05415917
Recruiting
Primary Objectives: To determine the disease free survival (DFS) for participants treated with post-operative adjuvant chemotherapy, as compared to neoadjuvant therapy alone. Secondary Objectives: To determine the clinical efficacy of the study treatment in terms of median overall survival (OS) and median disease free survival (DFS). To assess the safety and tolerability of the study treatment regimen as measured by the adverse events rates. To assess the quality of life in patients receivi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2023
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Conditions: Pancreatic Cancer
Register for Updates
A Dose Finding Study to Treat Bone Tumor(s)
NCT06008483
Recruiting
To determine the Maximum Tolerated Dose (MTD) of CycloSam®, Samarium-153-DOTMP (Sm-153-DOTMP), a radiopharmaceutical that delivers radiation to the bone when injected, given as a tandemly administered pair of doses to subjects with one or more solid tumor(s) in the bone or metastatic solid tumors to the bone that are visible on bone scan.
Gender:
ALL
Ages:
Between 15 years and 75 years
Trial Updated:
08/18/2023
Locations: Clinical Trial Site, New Brunswick, New Jersey
Conditions: Bone Cancer, Bone Tumor, Solid Tumor, Metastatic Cancer to the Bone, Metastatic Tumor to the Bone
Register for Updates
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
NCT05076942
Recruiting
Vulvar cancer patients with SN-metastasis \> 2mm will receive chemoradiation instead of an inguinofemoral lymphadenectomy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/27/2023
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey +2 locations
Conditions: Vulvar Cancer, Sentinel Lymph Node, Lymph Node Metastases
Register for Updates
Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer
NCT05232409
Recruiting
The purpose of the research is to determine the highest dose of an oral compound called zeaxanthin that can be safely taken each day in patients with advanced cancer, the toxicity profile of zeaxanthin, and the dose of zeaxanthin to use in future cancer clinical trials.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
04/19/2023
Locations: The Valley Hospital-Luckow Pavilion, Paramus, New Jersey
Conditions: Cancer Metastatic, Metastatic Solid Tumor
Register for Updates